microdosing semaglutide for perimenopause GLP-1s for Menopause-Related Weight Gain Microdosing GLP-1: A Next-Generation Approach

Should I stop b12 supplementation when I stop semaglutide

For semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, withdrawal symptoms tend to fall under the category of rebound effects

It is not a therapeutic endorsement, a claim of equivalence to SCENESSE, or a shortcut around regulated pathways

As with any pharmaceutical intervention, there are specific criteria and considerations for its use: Suitable candidates for cagrilintide treatment typically include: Adults with a Body Mass Index (BMI) of 30 or greater (classified as obese) Adults with a BMI of 27 or greater (overweight) with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia Individuals who have not achieved sufficient weight loss through diet and exercise alone Patients without contraindications to amylin analogs or GLP-1 receptor agonists (when used in combination) It's crucial to note that cagrilintide is not recommended for certain groups, including: Pregnant or breastfeeding women Individuals with a personal or family history of medullary thyroid carcinoma Patients with Multiple Endocrine Neoplasia syndrome type 2 Those with a history of pancreatitis or severe gastrointestinal disorders Before initiating treatment with cagrilintide, a comprehensive medical evaluation is necessary